search

Laura Moore-Schiltz, Ph.D., RDN

Senior Director, Health Economics and Outcomes Research

Laura Moore-Schiltz, Ph.D., RDN headshot - woman with mid-length hair smiling for headshot in a black blazer

Laura Moore-Schiltz, Ph.D., RDN, has more than 10 years of experience partnering with life sciences organizations to design observational research studies, health economic evaluations, and market landscape assessments.

Laura has extensive expertise using diverse real-world data sources, including administrative claims, electronic health records, and prospectively collected data, and has authored publications across therapeutic areas including oncology, rheumatology, endocrinology, gynecology, and infectious disease.

Prior to joining Inovalon, she served as an Outcomes Researcher at Ontada, where she led real-world oncology studies.

Laura also supported retrospective studies for life sciences partners as a Lead Analyst at IBM Watson Health. Earlier in her career, she worked as a Data Scientist for a health plan provider and as a Clinical Trial Manager for NIH- and industry-funded clinical trials.

Laura holds a Ph.D. in Epidemiology and Biostatistics and a Master of Science in Public Health Nutrition from Case Western Reserve University, as well as a Bachelor of Arts in Biology from The George Washington University.

Connect on LinkedIn
Authored Content
Placeholder
Oncology, real-world evidence

Receipt of SARS-Cov2 mRNA Vaccine Prior to Immune Checkpoint Inhibitor Therapy Associated With Significantly Improved Overall Survival Across Multiple Metastatic Cancers: Results From a Real-World Evidence Study

Accepted for presentation at International Society for Pharmacoeconomics and Outcomes Research. Findings available upon request. Contact us for more information.

Placeholder
Immunology

Incremental Direct and Indirect Costs of Sjögren’s Disease in the United States: A Retrospective Analysis Using MarketScan Databases

Accepted for presentation at International Society for Pharmacoeconomics and Outcomes Research. Findings available upon request. Contact us for more information.

Placeholder
Immunology

Flare Frequency, Organ Damage, and Economic Burden Among Individuals With Immunoglobulin G4-Related Disease (IgG4-RD) in the United States

Accepted for presentation at International Society for Pharmacoeconomics and Outcomes Research. Findings available upon request. Contact us for more information.

Businesswoman using laptop in office
Life Sciences

Inside the GLP-1 Boom: Trends in Off-Label Use from Inovalon Primary Source Data

Discover trends in off-label use of GLP-1 and patient demographics, uncovering who is driving the surge in prescriptions and its impact on healthcare.

Read More →
Share